Cited by 3,969Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Open access
Jones, Siân, Zhang, Xiaosong, Parsons, D. Williams, Lin, Jimmy Cheng-Ho, Leary, Rebecca J., Angenendt, Philipp, Mankoo, Parminder, Carter, Hannah +28 more·2008·Science

Abstract

There are currently few therapeutic options for patients with pancreatic cancer, and new insights into the pathogenesis of this lethal disease are urgently needed. Toward this end, we performed a comprehensive genetic analysis of 24 pancreatic cancers. We first determined the sequences of 23,219 transcripts, representing 20,661 protein-coding genes, in these samples. Then, we searched for homozygous deletions and amplifications in the tumor DNA by using microarrays containing probes for ∼10 6 single-nucleotide polymorphisms. We found that pancreatic cancers contain an average of 63 genetic alterations, the majority of which are point mutations. These alterations defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors. Analysis of these tumors' transcriptomes with next-generation sequencing-by-synthesis technologies provided independent evidence for the importance of these pathways and processes. Our data indicate that genetically altered core pathways and regulatory processes only become evident once the coding regions of the genome are analyzed in depth. Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.1164368

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Oncogenic KRAS mutations are the most common genomic alterations in PDAC, occurring in close to 90% of patients, followed by TP53, CDKN2A, and SMAD4.

    “Among the identified genomic alterations (GAs) in PDAC, oncogenic KRAS mutations are the most common, occurring in close to 90% of patients, followed by TP53, CDKN2A, and SMAD47,8.”
  • The PDAC genomic landscape is dominated by loss-of-function alterations in TP53, SMAD4, and CDKN2A.

    “the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [48]

  • Chromatin remodeling and SWI/SNF complex genes are among the most frequently altered classes of genes in PDAC and can occur via somatic deletions of associated chromosomal loci.

    “Chromatin remodeling and SWI/SNF complex genes are one of the most frequently altered class of genes in PDAC45,48–50, and can occur via somatic deletions of the associated chromosomal loci94.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [48]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. [11]Rubio-Viqueira B Clin Cancer Res 12 4652 2006 16899615
  2. [22]Leary RJ Proc Natl Acad Sci USA in press
  3. [33]Furukawa T Am J Pathol 148 1763 1996 8669463 PMC1861644
  4. [35]Owens AH Coffey DS Baylin SB Tumor Cell Heterogeneity Academic Press New York 1982
  5. [43]Contact information for the authors who directed the major components of this project is as follows: J. R. Eshleman, S. E. Kern (clinical and sample coordination), jeshlem@jhmi.edu, sk@mail.jhmi.edu; R. H. Hruban (pathological review), rhruban@jhmi.edu; R. Karchin (bioinformatic analysis), karchin@jhu.edu; N. Papadopoulos (gene expression analysis), npapado1@jhmi.edu; G. Parmigiani (statistical analysis), gp@jhu.edu; B. Vogelstein, V. E. Velculescu, K. W. Kinzler (sequencing and copy number analysis), bertvog@gmail.com, velculescu@jhmi.edu, kinzlke@jhmi.edu. We thank J. Ptak, N. Silliman, L. Dobbyn, M. Whalen, M. Borges, G. Cusatis, M. Griffith, C. Henderson, C. Karikari, G. Mo, M. Mullendore, E. Palmisano, M. Raben, S. Solt, and D. Trusty for expert technical assistance; T. Sjöblom for help with database management for mutational analyses; Y. Ding for help with bioinformatic analyses; and J. Cameron, G. Feldmann, S. Salaria, L. Hua, and C. Yeo for helpful discussions. This project was performed under the auspices of the Goldman Pancreatic Cancer Genome Initiative and was funded by the Sol Goldman Charitable Trust; the Lillian Goldman Charitable Trust; the Lustgarten Foundation for Pancreatic Cancer Research; the Virginia and D. K. Ludwig Fund for Cancer Research; the Susan G. Komen Foundation; the Michael Rolfe Pancreatic Cancer Foundation; the Joseph C. Monastra Foundation for Pancreatic Cancer; the family and friends of George Rubis; the Viragh Family Foundation; the Broad Foundation; the Emerald Foundation; NIH grants CA62924, CA43460, CA57345, and CA121113; and Beckman Coulter Corporation. Under separate licensing agreements between the Johns Hopkins University and Genzyme, Beckman Coulter, and Exact Sciences Corporations, K.W.K., B.V., and V.E.V. are entitled to a share of royalties received by the university on sales of products related to research described in this paper. These authors and the university own Genzyme and Exact Sciences stock, which is subject to certain restrictions under university policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.

Cited by

Sorted by citations

Authors
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S.-M., Fu, B., Lin, M.-T., Calhoun, E. S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D. R., Hidalgo, M., Leach, S. D., Klein, A. P., Jaffee, E. M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J. R., Kern, S. E., Hruban, R. H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., & Kinzler, K. W.
Affiliations
  • Sol Goldman Pancreatic Cancer Research Center, Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
  • Howard Hughes Medical Institute (US)
  • Russian Academy of Sciences (RU)
Corresponding author
  • Zhang, Xiaosong
  • Parsons, D. Williams
  • Lin, Jimmy Cheng-Ho
  • Leary, Rebecca J.
  • Angenendt, Philipp
  • Vogelstein, Bert
  • Velculescu, Victor E.
  • Kinzler, Kenneth W.
Venue
Science
Published
2008-09-26
Volume
321
Issue
5897
Pages
1801-1806
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W2138155367
Cited by
3,969
References
32
Citations by year
2026: 53 · 2025: 88 · 2024: 148 · 2023: 198 · 2022: 133 · 2021: 225 · 2020: 218 · 2019: 208 · 2018: 210 · 2017: 244 · 2016: 249 · 2015: 307 · 2014: 315 · 2013: 272 · 2012: 314
FWCI
137.42
Type
journal article
Language
en
Open access
Locations
  • Science (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Institutes of Health (5r01ca121113-15)
  • National Cancer Institute (CA 57345, R01-CA121113, CA-121113, CA43460, R37CA043460, P50CA062924, R37CA057345, CA 62924)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
pancreatic cancer, genetic alterations, point mutations, homozygous deletion, gene amplification, transcriptome, carcinogenesis, single nucleotide polymorphism array, next-generation sequencing
MeSH terms
Adenocarcinoma, Algorithms, Gene Amplification, Humans, Models, Molecular, Mutation, Pancreatic Neoplasms, Signal Transduction, Genome, Human, Point Mutation, Sequence Deletion, Computational Biology, Mutation, Missense, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Gene Expression Profiling, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review